FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3095878737> ?p ?o ?g. }

• W3095878737 endingPage "8" @default.
• W3095878737 startingPage "7" @default.
• W3095878737 abstract "Sickle cell disease (SCD) is a genetic disorder caused by inheritance of two alleles bearing a single nucleotide change in the β globin gene coding sequence. The pathophysiologic mechanism of SCD involves polymerization of intracellular hemoglobin S (HbS) following deoxygenation in the microvasculature, leading to decreased red blood cell (RBC) deformability, morphologic sickling of RBCs, decreased RBC survival, microvascular obstruction, and clinical complications (Bunn H, N Engl J Med, 1997). Voxelotor, a hemoglobin S polymerization inhibitor recently approved for the treatment of SCD, is an allosteric modifier of Hb that increases the proportion of oxygenated Hb in all RBCs. In clinical studies in subjects with SCD, voxelotor has demonstrated that doses of up to 1500 mg daily achieved Hb modifications of ~27%, was well tolerated, and resulted in reduced hemolytic anemia (Howard J et al., Blood, 2019; Vichinsky E et al., N Engl J Med, 2019). GBT021601 is a potent second generation HbS polymerization inhibitor with the potential to achieve even higher Hb modification in subjects with SCD at lower doses and therefore with less pill burden. To evaluate its effect on the pathophysiology of SCD, GBT021601 was administered at 20, 40, 75, and 150 mg/kg QD via oral dosing for 21 days in Townes SCD mice (SS mice). At steady state, GBT021601-treated SS mice achieved Hb occupancies (at Cmin) of 6%, 12%, 21%, and 29% corresponding to 20, 40, 75, and 150 mg/kg doses, respectively. This resulted in a dose-dependent reduction in p50 of SS mouse blood from ~28 mm Hg (vehicle-treated) to 11 mm Hg at the highest dose tested. Consequently, GBT021601 significantly reduced in vivo circulating sickled cells and ex vivo sickling of SS mouse blood under hypoxic conditions (20 mmHg). Consistent with its anti-polymerization activity, GBT021601 reduced hemolysis as demonstrated by 1) an increase in hemoglobin of up to 6.7 g/dL (Figure 1A), thereby achieving the normal range for wildtype mice, and 2) a reduction in the percentage of reticulocytes of up to 58% relative to vehicle-treated SS mice (Figure 1B). Additionally, GBT021601 treatment increased the percentage of mature RBCs and reduced the percentage of mitochondria-containing RBCs indicating an overall improvement in RBC health. Consistent with improved hemoglobin, reduced hemolysis, and improved RBC health, GBT021601 dose-dependently increased RBC half-life from 1.3 days in vehicle-treated SS mice to 7.4 days in SS mice treated with 150 mg/kg GBT021601 (Figure 1C). Furthermore, treatment of SS mice with GBT021601 for 21 days led to a significant reduction in spleen weight, indicating an improvement in splenic blood flow and organ function. Together, these data demonstrate that GBT021601, a next generation HbS polymerization inhibitor, normalized hemoglobin, reduced hemolysis and significantly improved RBC health, RBC half-life and organ function in a mouse model of SCD. These data support clinical development of GBT021601 as a potential best-in-class HbS polymerization inhibitor for SCD patients. Disclosures Dufu: Global Blood Therapeutics: Current Employment, Current equity holder in publicly-traded company. Alt:Global Blood Therapeutics: Current Employment, Current equity holder in publicly-traded company. Strutt:Global Blood Therapeutics: Current Employment, Current equity holder in publicly-traded company. Tang:Global Blood Therapeutics: Current Employment, Current equity holder in publicly-traded company. Liao-Zou:Global Blood Therapeutics: Current Employment, Current equity holder in publicly-traded company. Yuan:Global Blood Therapeutics: Current Employment, Current equity holder in publicly-traded company. Cathers:Global Blood Therapeutics: Current Employment, Current equity holder in publicly-traded company. Oksenberg:Global Blood Therapeutics: Current Employment, Current equity holder in publicly-traded company." @default.
• W3095878737 created "2020-11-09" @default.
• W3095878737 creator A5004438274 @default.
• W3095878737 creator A5017451220 @default.
• W3095878737 creator A5019483400 @default.
• W3095878737 creator A5041317994 @default.
• W3095878737 creator A5055599886 @default.
• W3095878737 creator A5055962857 @default.
• W3095878737 creator A5075473785 @default.
• W3095878737 creator A5088733732 @default.
• W3095878737 date "2020-11-05" @default.
• W3095878737 modified "2023-10-05" @default.
• W3095878737 title "GBT021601 Inhibits HbS Polymerization, Prevents RBC Sickling and Improves the Pathophysiology of Sickle Cell Disease in a Murine Model" @default.
• W3095878737 doi "https://doi.org/10.1182/blood-2020-140539" @default.
• W3095878737 hasPublicationYear "2020" @default.
• W3095878737 type Work @default.
• W3095878737 sameAs 3095878737 @default.
• W3095878737 citedByCount "2" @default.
• W3095878737 countsByYear W30958787372022 @default.
• W3095878737 countsByYear W30958787372023 @default.
• W3095878737 crossrefType "journal-article" @default.
• W3095878737 hasAuthorship W3095878737A5004438274 @default.
• W3095878737 hasAuthorship W3095878737A5017451220 @default.
• W3095878737 hasAuthorship W3095878737A5019483400 @default.
• W3095878737 hasAuthorship W3095878737A5041317994 @default.
• W3095878737 hasAuthorship W3095878737A5055599886 @default.
• W3095878737 hasAuthorship W3095878737A5055962857 @default.
• W3095878737 hasAuthorship W3095878737A5075473785 @default.
• W3095878737 hasAuthorship W3095878737A5088733732 @default.
• W3095878737 hasBestOaLocation W30958787371 @default.
• W3095878737 hasConcept C10162356 @default.
• W3095878737 hasConcept C126322002 @default.
• W3095878737 hasConcept C172680121 @default.
• W3095878737 hasConcept C203014093 @default.
• W3095878737 hasConcept C2776175824 @default.
• W3095878737 hasConcept C2776317666 @default.
• W3095878737 hasConcept C2778248108 @default.
• W3095878737 hasConcept C2778620579 @default.
• W3095878737 hasConcept C2778917026 @default.
• W3095878737 hasConcept C2779134260 @default.
• W3095878737 hasConcept C2779234561 @default.
• W3095878737 hasConcept C2779316324 @default.
• W3095878737 hasConcept C2780976302 @default.
• W3095878737 hasConcept C54355233 @default.
• W3095878737 hasConcept C71924100 @default.
• W3095878737 hasConcept C86803240 @default.
• W3095878737 hasConcept C98274493 @default.
• W3095878737 hasConceptScore W3095878737C10162356 @default.
• W3095878737 hasConceptScore W3095878737C126322002 @default.
• W3095878737 hasConceptScore W3095878737C172680121 @default.
• W3095878737 hasConceptScore W3095878737C203014093 @default.
• W3095878737 hasConceptScore W3095878737C2776175824 @default.
• W3095878737 hasConceptScore W3095878737C2776317666 @default.
• W3095878737 hasConceptScore W3095878737C2778248108 @default.
• W3095878737 hasConceptScore W3095878737C2778620579 @default.
• W3095878737 hasConceptScore W3095878737C2778917026 @default.
• W3095878737 hasConceptScore W3095878737C2779134260 @default.
• W3095878737 hasConceptScore W3095878737C2779234561 @default.
• W3095878737 hasConceptScore W3095878737C2779316324 @default.
• W3095878737 hasConceptScore W3095878737C2780976302 @default.
• W3095878737 hasConceptScore W3095878737C54355233 @default.
• W3095878737 hasConceptScore W3095878737C71924100 @default.
• W3095878737 hasConceptScore W3095878737C86803240 @default.
• W3095878737 hasConceptScore W3095878737C98274493 @default.
• W3095878737 hasIssue "Supplement 1" @default.
• W3095878737 hasLocation W30958787371 @default.
• W3095878737 hasOpenAccess W3095878737 @default.
• W3095878737 hasPrimaryLocation W30958787371 @default.
• W3095878737 hasRelatedWork W2019018139 @default.
• W3095878737 hasRelatedWork W2059114621 @default.
• W3095878737 hasRelatedWork W2080120796 @default.
• W3095878737 hasRelatedWork W2094736181 @default.
• W3095878737 hasRelatedWork W2147182596 @default.
• W3095878737 hasRelatedWork W2153336025 @default.
• W3095878737 hasRelatedWork W2319862760 @default.
• W3095878737 hasRelatedWork W2409009119 @default.
• W3095878737 hasRelatedWork W2755262585 @default.
• W3095878737 hasRelatedWork W4255144096 @default.
• W3095878737 hasVolume "136" @default.
• W3095878737 isParatext "false" @default.
• W3095878737 isRetracted "false" @default.
• W3095878737 magId "3095878737" @default.
• W3095878737 workType "article" @default.